What Angicam-Beta Treats: Main Uses and Benefits

Angicam-Beta is a medication prescribed to assist in the long-term management of cardiovascular conditions. It is commonly utilized in clinical scenarios involving high blood pressure (hypertension), where it helps maintain blood pressure within a target range. This action may help reduce the risks associated with sustained high blood pressure over time.

The medication is also an option for managing chest discomfort (angina). By including Angicam-Beta in their care plan, patients may experience management of the frequency and severity of angina episodes, which can contribute to improved daily physical function. The primary therapeutic uses for Angicam-Beta include hypertension, stable angina, and certain abnormal heart rhythms.

---

Quick Fact: Management for Hypertension and Angina

Eligibility Map: Who can and cannot use Angicam-Beta — official regulatory information

This fixed-dose combination is established for use in adult patients managing hypertension and angina. Use is not recommended for pediatric patients under 18 years, as efficacy and safety are not established for the combination product.

Absolute Contraindications prohibit use in individuals with known hypersensitivity to Amlodipine, Atenolol, or dihydropyridine derivatives. The medicine is also contraindicated in patients with acute conditions such as cardiogenic shock, severe hypotension, Second- or Third-Degree AV Block (without a pacemaker), severe bradycardia, and acute heart failure.

Conditional Use is required for several populations. Older adults require special caution and a cautious starting dose due to potential decreases in organ function. Use is restricted in patients with severe hepatic impairment and severe renal impairment (creatinine clearance below 30 mL/min). Pregnancy and lactation status is classified as not recommended.

Official Eligibility Statements: The regulatory profile strictly defines who can and cannot use this drug, focusing on pre-existing cardiovascular conditions, severe organ dysfunction, and age/reproductive status. The profile confirms use in adults while placing formal limitations on vulnerable populations.

Interactions with other medicines and products

The official regulatory profile for Angicam-Beta (Amlodipine/Atenolol) documents several clinically relevant interaction patterns based on pharmacokinetic and pharmacodynamic mechanisms.

Medicinal Product Interactions

Co-administration with potent or moderate CYP3A4 inhibitors (such as azole antifungals) may significantly raise the plasma concentration of the amlodipine component, increasing the potential for enhanced effects. Conversely, CYP3A4 inducers (like rifampicin) may lower amlodipine exposure. A strict dose limitation is imposed when co-administering Simvastatin, which must be restricted to a maximum of mathbf20 mg daily due to amlodipine's effect of significantly increasing Simvastatin exposure.

Combinations with other agents that reduce heart rate, conduction, or contractility (e.g., Verapamil, Digoxin) result in additive pharmacodynamic effects, which may exaggerate reductions in heart rate. The use of certain non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the effectiveness of the atenolol component. The co-administration of Dantrolene infusion is an officially restricted combination.

Food and Timing Constraints

Administration of atenolol requires separation by at least mathbf2 hours from certain antacids, such as Aluminum Hydroxide, to mitigate reduced absorption. Similarly, the consumption of Grapefruit or Grapefruit Juice is not recommended due to its potential to increase amlodipine exposure.

Population Considerations

Regulatory labeling notes that the risk of higher amlodipine exposure is relevant for patients with severe hepatic impairment, and reduced clearance of atenolol is a consideration in patients with renal impairment.

How Angicam-Beta Works

Atenolol acts as a selective beta1-adrenergic receptor antagonist, primarily targeting cardiac tissue. By competitively blocking these receptors, it reduces the activity of the sympathetic nervous system on the myocardium. This antagonism decreases the heart rate ( chronotropy) and the force of contraction ( inotropy), resulting in a reduction of the myocardial oxygen consumption.

Amlodipine exerts its mechanism by directly inhibiting L-type voltage-dependent calcium channels ( L-VDCCs) found on vascular smooth muscle cells. This blockade prevents calcium ions ( Ca^2+) from entering the cell, which is the molecular trigger for muscle contraction. The resulting arterial relaxation modulates the circulatory system's overall Systemic Vascular Resistance ( SVR) downward.

The fixed-dose combination modulates the two primary determinants of pressure: Cardiac Output ( CO) via Atenolol and SVR via Amlodipine. This synergy is complemented by Atenolol's action on beta1 receptors in the kidney, which leads to the suppression of renin release and limits the activation of the RAAS cascade.

The Angicam-Beta tablet is a fixed-dose combination (FDC) prescribed exclusively for oral administration. Proper use of this medication is based on a standardized daily schedule for long-term management.

Standard Administration and Dosing

• Dose and Frequency: The usual recommended regimen is one tablet once daily. The specific strength (e.g., Amlodipine 5 mg / Atenolol 50 mg) and any subsequent adjustments are based on the individual regimen.
• Timing: The tablet can be ingested with or without food at the same general time each day.
• Preparation: The tablet must be swallowed whole with water. It should not be crushed, broken, or chewed.

Special Population Instructions

Cautious use and potential dose modification are indicated for specific groups:

• Older Adults (Geriatric): Dosing should be initiated cautiously, often at the lower end of the dosing range.
• Hepatic Impairment: Because clearance of Amlodipine is prolonged, treatment should be started at a low dose and titration should proceed slowly.
• Renal Impairment: The Atenolol component may necessitate dose reduction if kidney function is severely impaired (creatinine clearance below 35 mL/min/1.73 m^2).
• Pediatric Patients: Use in children and adolescents (under 18 years) is not generally recommended.

Procedural Rules

Discontinuation: Abrupt withdrawal of Angicam-Beta is not advised. If treatment must be stopped, the dosage should be gradually reduced over a period of time under clinical observation.

Missed Dose: If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to maintain the regular daily schedule.

Research Evidence / Overview of Studies for Angicam-Beta

Evidence for use in High Blood Pressure (Hypertension)

Research examining the use of the Amlodipine/Atenolol fixed-dose combination (FDC) for high blood pressure was evaluated in Randomized Controlled Trials (RCTs) and systematic reviews. These studies were primarily applied in research contexts involving adult patients with mild to moderate essential hypertension, including those whose blood pressure was observed to be uncontrolled while receiving monotherapy. The principal outcomes evaluated included changes measured in Systolic and Diastolic Blood Pressure and the proportion of observed populations that reached predefined blood pressure goals.

The short-term trials (typically 4 to 8 weeks in duration) reported various measurements related to blood pressure metrics. Some comparative studies described patterns where the outcomes measured during combined use of the two active ingredients differed from those measured during use of either ingredient alone. Findings describe patterns observed in the studies related to blood pressure levels. Research describes changes measured during the study period, which contributes to the broader evidence landscape.

However, the evidence is limited, as FDC-specific studies primarily provide insight into intermediate endpoints over a limited number of weeks. Long-term effects are not fully established for this specific combination regarding long-term cardiovascular outcomes. Furthermore, the results apply only to the populations studied, and data for certain specialized groups remain insufficient.

---

Evidence for use in Chronic Stable Angina

The clinical research exploring this combination therapy for stable chest discomfort was evaluated in controlled trials, including specialized crossover studies. These studies focused on adult patients with stable angina pectorus who were experiencing signs of temporary reduced blood flow to the heart muscle, especially during physical activity. Study outcomes evaluated included functional measures such as exercise tolerance time, time to the onset of ST-segment changes (a marker of ischemia), and the patient-reported outcomes describing perceived discomfort related to the frequency and severity of anginal episodes.

The short-term trials (lasting up to approximately 10 weeks) reported how symptoms evolved in the observed populations related to physical discomfort. Studies focusing on episodes where symptoms become more noticeable explored outcomes when the combined therapy was compared to single-drug regimens and placebo in research exploring short-term symptom changes. Findings describe group patterns related to outcomes reflecting the impact of chest discomfort on daily functioning or activity level. Research provides insight into short-term changes that contributes to the broader evidence landscape.

Comparative evidence is lacking for a direct, long-term assessment of the FDC against many other established anti-anginal treatments. While data on the individual components’ long-term use is extensive, the long-term effects are not fully established for the specific fixed-dose combination regarding outcomes related to acute or disruptive episodes over many years.

---

Long-term Studies and Durability of Response

FDC-specific research studies generally have follow-up durations that were limited, often lasting only a few weeks to a few months. This means that the research primarily focuses on understanding measures of short-term outcomes like blood pressure control and exercise capacity. Data examining the durability of the measured effects over many years is not fully established by the specific combination trials themselves. Instead, insights into the long-term patterns of change are largely extrapolated from the individual component drug trials, which have extensive evidence histories in managing high blood pressure and angina.

---

Evidence in Specific Patient Populations

The research primarily includes adult patients with specific conditions. The results apply only to the populations studied, and data for certain groups remain insufficient. For instance, limited information is available from dedicated clinical trials for this combination in certain comorbid groups or those representing the extremes of age. There is also limited information for long-term outcomes in specialized subgroups, such as pregnant individuals or children, as these populations were generally excluded from the primary clinical trials.

---

What is Still Uncertain About the Research

Research summarizes what is known—and what is still uncertain—about this fixed-dose regimen. The data remain limited for certain specialized outcomes, and long-term effects are not fully established for this specific combination regarding long-term cardiovascular outcomes. Some findings were mixed when the FDC was directly compared to taking the two individual medications as separate pills for some outcomes. Research exploring these short-term symptom changes helps provide context, but research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE): Hypertension in Adults: Diagnosis and Management (Guideline NG136)

Common questions about Angicam-Beta (FAQ)

Q: What is the typical timeframe before Angicam-Beta starts to noticeably lower blood pressure?

A: According to official product information, the medicine starts working in the body from the day it is first taken. However, because blood pressure management requires ongoing treatment, it may take several weeks to experience the full effect.

Q: Are there generic versions of Angicam-Beta available?

A: The two active ingredients in Angicam-Beta, Amlodipine and Atenolol, are both widely available as generic medications. This indicates that generic alternatives containing the same active components are generally available.

Q: Is Angicam-Beta used to prevent heart attacks or strokes?

A: In adults with hypertension, lowering blood pressure with this medication is associated with a reduced risk of certain serious cardiovascular events over time, such as strokes and heart attacks. This information is consistent with findings in clinical studies and regulatory documentation.

Q: What research supports the combined use of Amlodipine and Atenolol for hypertension?

A: Regulatory guidelines support the use of this combination in managing hypertension when treatment with a single drug is considered insufficient. This fixed-dose combination strategy leverages the distinct actions of the two different drug classes to achieve blood pressure control.

Q: Is it common for people to need a change in their Angicam-Beta dosage over time?

A: Dosages are subject to periodic review by a healthcare professional. Adjustments may be made depending on the individual's response to the medication or if other long-term medications are initiated or discontinued.

Q: Does Angicam-Beta help with exercise tolerance for people with angina?

A: Studies have shown that the Amlodipine component can be associated with increased exercise time and a longer duration until the onset of chest discomfort during activity in observed patient groups. This contributes to the overall management of chronic stable angina.

Q: Is Angicam-Beta a drug that is considered habit-forming?

A: Angicam-Beta is not classified as a controlled substance by regulatory agencies. Therefore, it is not considered a habit-forming or addictive medication in official regulatory documentation.

Q: Does Angicam-Beta have the same ingredients as 'Angicam' (without the Beta)?

A: No. Angicam-Beta is a fixed-dose combination containing two active ingredients: Amlodipine and Atenolol. The product named 'Angicam' typically contains only the single ingredient, Amlodipine.

Q: Does Angicam-Beta interact with any common herbal supplements?

A: Regulatory information indicates that the herbal remedy St. John’s wort may have the potential to interfere with the effect of the Amlodipine component. Reviewing all medications and supplements with a healthcare professional is recommended.

Q: How long does the effect of one tablet of Angicam-Beta typically last?

A: Both active ingredients, Amlodipine and Atenolol, are long-acting compounds. The medication is dosed once daily, as it is designed to maintain its therapeutic effects on blood pressure and heart rate over a 24-hour period.

Q: What are the possible signs of the body adjusting to the medication in the first few weeks?

A: Side effects may occur as patients begin treatment, which can be interpreted as the body adjusting to the medication. These can include feelings of dizziness, lightheadedness, or fatigue, which are most likely to be noted at the start of therapy.

Q: Why is the use of alcohol generally limited while taking Angicam-Beta?

A: Regulatory information indicates that alcohol can independently lower blood pressure. This may have an additive effect when combined with this medication, increasing the risk of symptoms like lightheadedness or fainting.

Q: Can Angicam-Beta be used by people who also have asthma or other breathing problems?

A: Due to the Atenolol component (a beta-blocker), regulatory information advises that its use requires caution or is restricted in individuals with certain breathing issues. The use of beta-blockers in patients with conditions such as asthma or chronic obstructive pulmonary disease (COPD) is generally not recommended.

Q: Why is Angicam-Beta often used when a single blood pressure medication is not enough?

A: The combination is used because the two active ingredients work together to provide a complementary effect, often addressing blood pressure more comprehensively than single-drug therapy. One component relaxes blood vessels, and the other slows the heart rate.

Official Storage and Disposal Requirements

Angicam-Beta tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medication must be protected from excess heat, moisture, and direct light, and it is explicitly stated that the product must not freeze.

Storage must occur in the original container and be kept tightly closed to maintain product stability until the labeled expiration date. For safety, the medication must be stored out of the sight and reach of children.

Unused or expired Angicam-Beta must be disposed of according to local regulations. The preferred method is utilizing an official drug take-back program or a mail-back envelope. It must not be flushed down a toilet or poured into a drain.